BioSpace News Archive

According to the most recent analysis by Emergen Research, the global market for microbial bioremediation had a value of USD 46,865.2 million in 2021 and is projected to grow at a rate of 11.0 percent during the forecast period.

Rising cases of cancer worldwide and increasing government initiatives to raise cancer awareness among the population are some of the key factors expected to drive Immunocytokines market revenue growth.

Forecast to 2030,’ thoroughly examines the Prostate Biopsy Devices industry to provide essential data & information for the targeted readers.

Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the database lock for the phase 3 clinical trial of the investigational visual cycle modulator emixustat hydrochloride (emixustat) in patients with Stargardt Disease.

No hospital has a monopoly on good ideas. This is why the St. Baldrick’s Foundation funds the most promising research — no matter where it takes place – from your backyard institution to other cutting edge research facilities treating childhood cancers around the globe.

Viz.ai, the leading AI-powered disease detection and intelligent care coordination platform, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz Subdural (SDH).

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, reiterated today what it had previously disclosed in 2021, that certain government agencies had requested information from the Company.

The company will focus in the coming months on negotiating a Series A round of €7 million to finance market entry, complete clinical validation and expand the product portfolio.

If you want to track a person’s activities for a day, you could call them up every ten minutes and ask what they’re doing.

Innova Medical Group, Inc., a global health innovator and a world leader in the development and distribution of rapid diagnostic tests and other medical devices, announced today the appointment of Robert A. Kasprzak as the company’s Chief Executive Officer, following his role Chief Legal Officer since the company’s inception.